DB18566ExperimentalCell transplant therapies
MB-107 consists of mobilized peripheral blood-derived autologous CD34+ hematopoietic stem cells that are genetically modified to express the IL2RG gene.
- Code names
- MB-107
Resolves to
Compound
Which companies are running trials of MB-107, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account